<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04434781</url>
  </required_header>
  <id_info>
    <org_study_id>1708840627</org_study_id>
    <nct_id>NCT04434781</nct_id>
  </id_info>
  <brief_title>Gastric Per-Oral Endoscopic Myotomy (G-POEM) for the Treatment of Gastroparesis</brief_title>
  <acronym>G-POEM</acronym>
  <official_title>Gastric Per-Oral Endoscopic Myotomy (G-POEM) for the Treatment of Gastroparesis: A Database Repository</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastric Per-Oral Endoscopic Myotomy (G-POEM) is a procedure for the Treatment of&#xD;
      Gastroparesis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastroparesis is a disease of the stomach where there is significant delay in gastric&#xD;
      emptying of contents to the intestines. This disease results in a multitude of symptoms&#xD;
      including nausea, vomiting, weight loss, and malnutrition.&#xD;
&#xD;
      Current treatments for gastroparesis include dietary changes, oral medications (prokinetic&#xD;
      agents to enhance gastric motility, acid reducers, anti-emetics to reduce nausea and&#xD;
      vomiting), gastric stimulators and rarely surgery.&#xD;
&#xD;
      G-POEM (Gastric Per-Oral Endoscopic Myotomy-creating a cut in the muscle that controls&#xD;
      gastric emptying), an incision-less (no cutting of the surface of the body) endoscopic&#xD;
      procedure, is increasingly being performed to assist in the management of certain groups of&#xD;
      patients with gastroparesis.&#xD;
&#xD;
      This data will be used for research purposes only to determine the clinical impact of&#xD;
      endoscopic treatments on gastroparesis. The physicians will also be able to better understand&#xD;
      the patient's condition and disease process that may lead to improved standard of care and&#xD;
      improved patient management.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 7, 2018</start_date>
  <completion_date type="Anticipated">August 15, 2026</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Change in Gastroparesis Cardinal Symptom Index (GCSI) from baseline to post G-POEM</measure>
    <time_frame>60 months span: baseline and assess change at 1 month, 3 month, 6 month, 12 month, 24 month, 36 month, 48 month &amp; 60 months</time_frame>
    <description>The Gastroparesis Cardinal Symptom Index (GCSI) is used for assessing severity of symptoms associated with gastroparesis. Patients are to score each of the 9 symptom criteria on 0 (None) to 5 (Very Severe) Likert Scale. The higher the score the more symptomatic from gastroparesis the patient is.&#xD;
Nausea or Vomiting (score 0-5 for each of the following 3 criteria)&#xD;
Nausea&#xD;
Retching&#xD;
Vomiting Postprandial fullness or early satiety (score 0-5 for each of the following 4 criteria)&#xD;
Stomach Fullness&#xD;
Not able to finish a normal-sized meal&#xD;
Feeling excessively full after meals&#xD;
Loss of appetite Bloating (score 0-5 for each of the following 2 criteria)&#xD;
Bloating&#xD;
Stomach visibly larger</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Change in Patient Assessment of gastrointestinal disorders-symptom severity index (PAGI-SYM) score from baseline to post G-POEM</measure>
    <time_frame>60 months span: baseline and assess change at 1,3,6,12,24, 36,48 &amp; 60 months</time_frame>
    <description>Change in PAGI-Sym score: The PAGI-SYM is composed of 20 items and 6 subscales: heartburn/regurgitation (7 items), nausea/vomiting (3 items), postprandial fullness/early satiety (4 items), bloating (2 items), upper abdominal pain (2 items), and lower abdominal pain (2 items). Subscale scores are calculated by averaging across items comprising the subscale; scores vary from 0 (none or absent) to 5 (very severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Change in G-POEM SF-36 Health Survey score from baseline to post G-POEM</measure>
    <time_frame>baseline and assess change at 1,3,6,12,24,36,48 &amp; 60 months</time_frame>
    <description>Change in health belief questionnaire (SF-36) score: Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability and the higher scores indicate better health</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of change in Gastric Emptying Scan (GES) (solid phase, 4 hour study) from baseline to post G-POEM</measure>
    <time_frame>baseline; and assess change at 6, and 24 months</time_frame>
    <description>we will track change in GES at 6 months and 24 months post G-POEM and compare to baseline. Normal GES should have under 5% at 4 hours</description>
  </primary_outcome>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Gastroparesis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        As long as patients fall under the inclusion criteria and do not fall under exclusions,&#xD;
        every patient can be considered. Patient must be declared safe to undergo procedure on&#xD;
        individual basis from an evaluation from head doctor on study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age&#xD;
&#xD;
          -  Referral for endoscopic treatment of Gastroparesis for symptom management&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt; 18 years of age&#xD;
&#xD;
          -  Absence of gastroparesis based on scintigraphy studies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammad Al-Haddad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohammad Al-Haddad, MD</last_name>
    <phone>317-944-0980</phone>
    <email>moalhadd@iu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ariel Quickery, MS</last_name>
    <phone>317-944-0980</phone>
    <email>aquicker@iu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Indiana University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad Al-Haddad, MD</last_name>
      <phone>317-944-0980</phone>
      <email>moalhadd@iu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 10, 2018</study_first_submitted>
  <study_first_submitted_qc>June 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 17, 2020</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Mohammad Al-Haddad</investigator_full_name>
    <investigator_title>Associate Professor of Medicine, Associate Clinical Director</investigator_title>
  </responsible_party>
  <keyword>GPOEM</keyword>
  <keyword>Gastric Per-Oral Endoscopic Myotomy</keyword>
  <keyword>Myotomy</keyword>
  <keyword>Gastroparesis</keyword>
  <keyword>g-poem</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

